SELLAS Life Sciences stock volatility reflected investor focus on unresolved binary clinical milestones rather than confirmed negative results. In a report on the company’s sharp decline, the analysis pointed to risk reduction ahead of a Phase 3 REGAL event-driven readout for galinpepimut-S maintenance therapy in acute myeloid leukemia, with 78 of 80 prespecified events reached in May and the 80th event still pending. The same coverage noted that SELLAS is also dosing in a Phase 2 SLS009 trial (tambiciclib) in newly diagnosed first-line AML, with topline timing still expected in the fourth quarter. For biotech investors, the takeaway was clear: even when no failure is publicly filed, event timing and the market’s expectations around unblinded data can dominate trading until the company updates the record.